Our goal is to relieve pain and help patients regain function without surgery. We create personalized care plans to address each ...

Philips' smart systems and intelligent software showcased at Arab Health 2025 is developed to enable predictability, collaboration, precision, and integration to deliver better care for more people ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Back pain is the most common complaint in a pain ... To achieve this view, adjust the c-arm in an anteroposterior view with 10–15° oblique to the ipsilateral side and 15–25° to the caudade.

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Samaritan Medical Center is closing its Pain Management Center at the end of February. SMC says the center “is not meeting ...

Watertown, N.Y.-based Samaritan Health will close its pain management center Feb. 28, according to a news release from the health system. The center, which has 15 employees and one contracted ...